Drug Profile

NB 002 - Nysnobio

Alternative Names: NB-002 - Nysnobio

Latest Information Update: 19 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

19 Feb 2025 Preclinical trials in Parkinson's disease in USA (Parenteral) (NysnoBio pipeline, February 2025)
19 Feb 2025 NysnoBio plans to initiate a phase I trial for Parkinson's Disease in Second quarter of 2027 (Parenteral) (NysnoBio pipeline, February 2025)
18 Sep 2023 NysnoBio plans to files an IND application for Cancer in the second quarter of 2024 (NysnoBio pipeline, September 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com